Press Release

<< Back
View printer-friendly version

Spark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to Discuss Second Quarter 2016 Results

PHILADELPHIA, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, August 10, 2016 at 8:30 a.m. ET to report corporate and financial results for the three and six months ended June 30, 2016. 

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 58493009.  To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 58493009 or also available on our website.

About Spark Therapeutics

Spark Therapeutics, a fully integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark Therapeutics’ validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases.  Spark Therapeutics’ validated and proprietary technology platform for selecting, designing, manufacturing and formulating highly optimized gene therapies has successfully delivered gene therapies with proof-of-concept data in the eye and liver. Spark Therapeutics’ most advanced product candidate, voretigene neparvovec (formerly referred to as SPK-RPE65), which has received both breakthrough therapy and orphan product designation, reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark Therapeutics’ hemophilia franchise has two lead assets: SPK-9001, in a Phase 1/2 trial for hemophilia B and SPK-8011, a preclinical candidate for hemophilia A.  To learn more, please visit www.sparktx.com.

Contacts

Corporate Contacts:

Stephen W. Webster
Chief Financial Officer
Spark Therapeutics, Inc.Dan Faga
Chief Business Officer
Spark Therapeutics, Inc.

(855) SPARKTX (1-855-772-7589)

Media Contact:

Ten Bridge CommunicationsDan Quinn
(781) 475-7974
dan@tenbridgecommunications.com

Primary Logo

Spark Therapeutics, Inc.